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Objectives. The purpose of this study was to investigate whether
therapy with nitroglycerin (GTN) would lead to abnormal coro-
nary artery responses to the endothelium-dependent vasodilator
acetylcholine.
Background. Nitroglycerin therapy is associated with specific
biochemical changes in the vasculature that may lead to increased
vascular sensitivity to vasoconstrictors.
Methods. Patients were randomized to continuous transdermal
GTN, 0.6 mg/h (n 5 8), or no therapy (n 5 7), for 5 days prior to
a diagnostic catheterization. Patients had similar risk factors for
endothelial dysfunction. Quantitative angiography was performed
in the morning to measure the mean luminal diameter of the left
anterior descending coronary artery (LAD) in response to intra-
coronary acetylcholine (peak concentration, 1024 mol/liter). The
transdermal preparation was removed from the GTN group, and
3 h later experimental procedures were repeated.
Results. In the morning, the GTN group experienced greater
coronary constriction in response to acetylcholine infusion than
those not receiving GTN (219.6 6 4.2 vs. 23.8 6 3.0%; p 5 0.01).
Three hours later, the GTN group continued to display greater
constriction to acetylcholine (224.1 6 5.9%) as compared to the
non-GTN group (21.8 6 4.8%). When the morning and afternoon
responses to acetylcholine were compared, the increase in coro-
nary constriction in the GTN group was greater than the change
observed in the non-GTN group (p < 0.05).
Conclusions. This study demonstrates that therapy with GTN
causes abnormal coronary vasomotor responses to the
endothelium-dependent vasodilator acetylcholine, changes that
were persistent for up to 3 hours after GTN discontinuation. This
nitrate-associated vasomotor dysfunction has implications with
respect to the development of nitrate tolerance and the potential
for adverse events during nitrate withdrawal.
(J Am Coll Cardiol 1998;32:1969–74)
©1998 by the American College of Cardiology
The organic nitrates are important agents in the therapy of
coronary artery disease and congestive heart failure. Given
acutely, they have potent hemodynamic and therapeutic effects
that result from dilatation of venous and arterial vascular beds.
A major limitation to their use is the development of tolerance,
with loss of effectiveness during sustained therapy. Although a
number of theories have developed concerning the mechanism
of tolerance, the cause remains uncertain (1,2). In addition to
this uncertainty, it is now recognized that therapy with nitrates
is associated with increased vascular sensitivity to vasoconstric-
tion (3,4). The mechanism of this increased sensitivity remains
unknown, although animal models have demonstrated that
exposure to nitroglycerin (GTN) is associated with increased
vascular content of endothelin-1 as well as increased superox-
ide anion production by the endothelium (4,5). Importantly,
Heitzer et al. (6) have demonstrated that treatment with GTN
increases vasoconstrictor responses to both phenylephrine and
angiotensin II in the human forearm.
These findings suggest that nitrate therapy may modify
vascular responses in the coronary circulation and increase its
sensitivity to vasoconstriction. Such responses may be involved
in the genesis of tolerance and could provide an explanation
for adverse events that have been reported following nitrate
withdrawal (7–11). The present study tests the hypothesis that
therapy with GTN would increase epicardial coronary sensitiv-
ity to the vasoconstrictor effects of acetylcholine and that this
effect would be exaggerated following GTN withdrawal.
Methods
Study population. Patients between 35 and 75 years of age,
referred for coronary angiography, were eligible for participa-
tion in the study. Clinical exclusion criteria were uncontrolled
hypertension; symptomatic congestive heart failure or severe
left ventricular dysfunction; history of coronary spasm; myo-
cardial infarction or unstable angina within 30 days of random-
ization; second- or third-degree AV block; transluminal revas-
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cularization procedures in the previous 6 months; any previous
transluminal revascularization of the left anterior descending
coronary artery (LAD); coronary artery bypass grafting; type I
diabetes mellitus; and clinically significant renal or hepatic
disease. Thirty-seven patients were initially enrolled. One
patient withdrew consent prior to the angiogram, and a second
was withdrawn because of newly diagnosed anaemia. At the
time of angiography, 20 patients were found to have more than
a 25% diameter stenosis of the left main coronary or more
than a 40% diameter stenosis in the LAD and were excluded
because they were believed to be ineligible for intracoronary
acetylcholine infusions based on the severity of their coronary
artery disease. Therefore, 15 patients completed the protocol.
Risk factors for endothelial dysfunction. The total number
of known risk factors for endothelial dysfunction was assessed
for each patient. These factors included age .45 years, male
sex, history of hypertension, noninsulin-dependent diabetes
mellitus, current cigarette smoking, family history of prema-
ture coronary artery disease, and total cholesterol .5.3 mmol/
liter. Serum lipid concentrations were evaluated in the fasting
state at the time of angiography.
Study protocol. Placebo transdermal GTN preparations
could not be obtained. Therefore, patients were randomly
assigned to receive continuous transdermal GTN (Ciba-Geigy,
Mississauga, Ontario), 0.6 mg/h, or no treatment in an
investigator-blind fashion. The GTN patch was applied each
morning and replaced every 24 h for 5 days. Patients receiving
long-acting nitrates prior to randomization had their nitrate
withdrawn at least 1 week prior to the day of the study. Other
vasodilators were discontinued for 48 h prior to the angiogram,
and beta-blockers were discontinued for 24 h. Patients were
allowed to use sublingual GTN as required for angina, but no
study was carried out within 6 h of GTN use. Vitamin C and E
supplements were discontinued 7 days prior to the study.
The angiogram was performed on the morning of the fifth
day, at approximately 9:00 AM. In those randomized to GTN,
the transdermal preparation was left in place during the
morning study. Coronary angiography was performed with 7F
diagnostic catheters using Judkin’s technique. Once angio-
graphic suitability for the study had been confirmed, a single
view best demonstrating the proximal and mid-portion of the
LAD coronary artery was selected for each patient and used
for the subsequent study angiograms. Heart rate, femoral
arterial pressure, and electrocardiographic (ECG) leads I, II
and V5 were continuously monitored.
Quantitative coronary angiograms were performed in the
control state and after serial acetylcholine chloride infusions.
Control and acetylcholine solutions were infused at
1.25 ml/min for 3 min into the left main coronary artery via the
diagnostic catheter in the following sequence: 1) control: 5%
dextrose in water, the vehicle for acetylcholine infusion; 2)
three incremental acetylcholine infusions: concentrations of
1026, 1025, and 1024, mol/liter to achieve intracoronary con-
centrations of 1028, 1027, and 1026 mol/liter, assuming a left
coronary blood flow of 125 ml/min; 3) recontrol: 5% dextrose
in water. Angiography was repeated immediately after com-
pletion of each infusion. A 3-min time period was allowed to
elapse between each angiogram and the following infusion, to
compensate for contrast medium-induced changes in coronary
tone.
Immediately following the completion of the morning
study, the GTN patch was removed from patients in the GTN
group. Three hours later, patients were returned to the cath-
eterization laboratory and underwent identical intracoronary
drug infusions using the same projection and radiographic
technique as had been done in the morning.
The study protocol was approved by the Committee on
Human Subjects Experimentation of the University of To-
ronto, and written informed consent was obtained from all
patients.
Quantitative measurements. Left coronary artery angio-
grams were performed by power injection (Medrad, Pitts-
burgh, Pennsylvania) of 9 to 12 ml (3 to 4 ml/s) of nonionic
contrast medium. Quantitation of coronary dimensions was
performed using an automated edge detection system (CMS,
Neunen, The Netherlands) and techniques previously reported
by our laboratory (12). A single end-diastolic frame of each
angiogram was selected by an investigator blinded to the study
groups. The longest, clearly visualised segment of the proximal
to mid-LAD was selected. In the GTN group, the mean length
of the analyzed segment was 4.3 6 0.6 cm; it was 4.4 6 0.4 cm
in the non-GTN group. The proximal and distal boundaries of
the selected segments were referenced to precise anatomical
landmarks to ensure replication of the analysis. The mean
luminal diameter of the LAD segment was recorded from each
study angiogram. An untapered portion of the contrast
medium-filled 7F coronary catheter was filmed before each
angiogram and used for calibration. All films were analyzed by
a blinded technician. In our laboratory, coronary artery diam-
eter measurements performed with this system have interob-
server variability of 0.09 mm, and intraobserver variability of
0.01 mm on repeated analysis of the same frame.
Statistical analysis. Baseline characteristics were com-
pared using unpaired t tests for continuous variables. A
Fischer’s exact test was used to compare binary variables.
Changes in mean luminal diameter from control values to each
dose of acetylcholine were compared using a multivariate
analysis of variance (MANOVA) within a general linear model
procedure, with appropriate contrast statements (PROC
GLM, MANOVA, SAS release 6.11, SAS Institute, Cary,
North Carolina). This model allowed for analysis of between-
group changes in the responses to acetylcholine for both the
morning and afternoon angiograms. Furthermore, differences
between groups in the overall response to acetylcholine during
the morning, versus the afternoon, could also be compared.
Abbreviations and Acronyms
GTN 5 nitroglycerin
LAD 5 left anterior descending coronary artery
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Finally, the procedure also allowed for univariate comparisons
at baseline and all subsequent time points between groups.
Within-group changes of mean luminal diameter were com-
pared using a paired t test. All comparisons were made for
changes in absolute values as well as percent changes from
baseline. A two-sided p value of ,0.05 was considered to be
significant. Data are expressed as mean 6 SE.
Results
Baseline patient characteristics. Eight patients were ran-
domized to GTN therapy (five men; aged 56 6 4 years) and
seven to the non-GTN arm (five men; aged 62 6 3 years).
There were no significant differences between groups in terms
of known risk factors for endothelial dysfunction (Table 1). All
patients in the GTN group, and six patients in the non-GTN
group, had atherosclerosis with intimal irregularities of the
LAD. The average LAD stenosis was 8.8 6 2.8% in the GTN
group and 12.9 6 6.0% in the non-GTN group. The groups
were well matched in terms of concomitant medications at the
time of randomization, with one patient in each group receiv-
ing angiotensin-converting enzyme inhibitors, vitamin supple-
mentation and estrogen replacement therapy. Baseline heart
rate and blood pressure at the time of both the morning and
afternoon studies were similar in the two groups (not shown).
Clinical response to acetylcholine infusion. In the morning
study, two patients in the GTN group developed angina
associated with moderate coronary constriction during infusion
of the maximal concentration of acetylcholine. In both cases,
angina resolved with termination of the infusion, and no
intracoronary GTN was given. In the afternoon study, the same
two patients and one additional patient developed angina in
response to the maximal acetylcholine infusion in the GTN
group. In two of these patients the angina was severe, did not
improve with discontinuation of the acetylcholine infusion, and
required intracoronary GTN. In the non-GTN group, no
significant chest pain was observed during any acetylcholine
infusion.
Coronary diameter responses. The infusion of acetylcho-
line, 1026 mol/liter, caused no significant change in mean
luminal diameter of the LAD in either group, and this data is
not presented. During the morning angiogram there was no
difference between groups in control values for the diameter of
the LAD (2.35 6 0.14 vs. 2.21 6 0.13 mm; p 5 NS). In the
non-GTN group there was no significant change in the mean
luminal diameter of the LAD during acetylcholine infusion. In
contrast, in those receiving transdermal GTN, a highly signif-
icant decrease occurred in mean luminal diameter at the peak
acetylcholine infusion rate (p , 0.01 vs. control) (Fig. 1). This
decrease in mean luminal diameter of the LAD was signifi-
cantly different from the change observed in the non-GTN
group (p , 0.01). Similar results were observed when the
responses were expressed as percent change (Fig. 2).
In the afternoon, 3 h after removal of transdermal GTN,
the control diameter of the LAD was significantly smaller than
was the control value for the morning angiogram in the GTN
group (2.35 6 0.14 vs. 2.03 6 0.09 mm; p , 0.01). In the
non-GTN group, there was no change in LAD diameter
between the two control periods. In response to intracoronary
acetylcholine in the afternoon study, there was no significant
change in LAD diameter in the non-GTN group (Fig. 3). The
GTN group, now 3 h after GTN patch removal, experienced
highly significant decreases in LAD diameter in response to
acetylcholine at both the 1025 and 1024 mol/liter concentra-
tions (p , 0.01 vs. control). These decreases in LAD diameter
were significantly different from those observed in the non-
Table 1. Demographic, Clinical and Laboratory Characteristics of the Study Groups
Characteristic
GTN Group
(n 5 8)
Non-GTN Group
(n 5 7) p Value
Age 56 6 4 62 6 3 NS
Sex (M/F) 5/3 5/2 NS
History of hypertension 2 3 NS
Non-insulin-dependent diabetes 3 2 NS
Family history of CAD 2 2 NS
Total cholesterol .5.3 mmol/liter 3 4 NS
History of smoking
Current 1 1 NS
Former 3 3 NS
Total number of risk factors* 3.1 6 0.4 3.3 6 0.4 NS
History of MI 2 1 NS
History of coronary angioplasty 1 1 NS
Serum cholesterol, mmol/liter
Total 5.2 6 2.5 5.4 6 0.5 NS
HDL 1.1 6 0.1 1.2 6 0.2 NS
LDL 3.6 6 0.3 3.3 6 0.4 NS
Triglycerides, mmol/liter 1.2 6 0.2 1.9 6 0.3 NS
Values are mean 6SE. *Risk factors: age .45 years, male sex, history of hypertension, non insulin-dependent
diabetes, family history of CAD, total cholesterol .5.3 mmol/liter, current smoker. CAD, coronary artery disease; GTN,
nitroglycerin; HDL, high-density lipoprotein; LDL, low-density lipoprotein; MI, myocardial infarction.
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GTN group (p , 0.01). Again, similar results were observed
when the responses were expressed as percent change. In the
GTN group, the LAD diameter at 1024 mol/liter concentration
was significantly smaller in the afternoon than in the morning
(1.54 6 0.13 vs. 1.89 6 0.15 mm; p , 0.01).
When the morning and afternoon coronary responses to
acetylcholine were compared, the between-group analysis re-
vealed that the increase in coronary vasoconstriction in the
GTN group was significantly different from the change ob-
served in the non-GTN group. This difference was apparent
when the data was analyzed using both absolute and percent
changes in LAD diameter (p , 0.05 for both). In response to
intracoronary GTN bolus, both groups presented similar LAD
dilatation (14.8 6 2.0 vs. 16.2 6 5.4% for GTN and non-GTN
groups, respectively; p 5 NS).
Discussion
We have demonstrated that therapy with transdermal GTN
is associated with increased epicardial coronary artery constric-
tion in response to acetylcholine and that this response was
persistent 3 h after GTN discontinuation. The coronary re-
sponses to GTN demonstrated that endothelial-independent
vasodilatation was preserved in both groups.
Endothelial dysfunction. Coronary vasoconstriction in re-
sponse to acetylcholine is an accepted marker for endothelial
dysfunction that occurs in the setting of a number of disease
states (13–20). Abnormal endothelial function appears to be
associated with the development of atherosclerosis and unsta-
ble coronary syndromes (20). The cause(s) of endothelial
dysfunction remain unclear, but several independent risk fac-
tors have been identified (20,21). The finding that therapy with
GTN is associated with increased vasoconstriction in response
to an endothelium-dependent vasodilator is unique, and it has
potentially important clinical implications.
Mechanism of acetylcholine responses. The mechanism of
increased coronary constriction to acetylcholine during therapy
with GTN is unknown. This response could result from an
increase in the sensitivity of smooth muscle to the vasocon-
strictor actions of acetylcholine, a change in nitric oxide
metabolism that reduces the amount of nitric oxide available
following exposure to acetylcholine, or some combination of
these effects. Recently, Mu¨nzel et al. (5) demonstrated that
therapy with GTN leads to an increase in superoxide anion
production in the endothelium of rabbit aortae. They hypoth-
esize that increased free radical production diminishes the
effects of nitrates via inactivation of GTN-derived nitric oxide.
Similarly, this increased free radical production associated with
GTN therapy could lead to inactivation of endothelial nitric
oxide released by acetylcholine. Other studies have demon-
strated that nitrate exposure increases vascular sensitivity to a
number of vasoconstrictors (3,4).
In humans, it has been reported that forearm resistance
vessels are more sensitive to the vasoconstrictor effects of both
phenylephrine and angiotensin II during therapy with intrave-
nous GTN (6). Although the mechanism of this hypersensitiv-
ity is not known, Mu¨nzel et al. have provided evidence that it
is mediated by increased autocrine production of endothelin-1,
a potent vasoconstrictor peptide that may play a role in the
abnormal endothelial-dependent vasomotor responses associ-
ated with atherosclerosis (4,22). Although it is not possible to
draw conclusions concerning the mechanism of the abnormal
coronary vasomotor responses to acetylcholine in the present
study, available experimental data provides a clear rationale.
GTN withdrawal. Another important finding of this study
is that GTN withdrawal may further increase the sensitivity of
the coronary vasculature to the vasoconstrictor effects of
acetylcholine. The smaller diameter of the LAD during maxi-
mal acetylcholine infusion in the afternoon was associated with
occurrence of angina in the GTN group. Such abnormal
endothelium-dependent coronary vasomotor responses during
the nitrate-free period may be playing a role in previous
Figure 1. Absolute change in mean luminal diameter of the left
anterior descending artery (LAD) coronary artery during intracoro-
nary infusions. Ach25 and Ach24 indicate intracoronary acetylcholine
infusions, 1025 and 1024 mol/liter, respectively. E 5 Nitroglycerin
group.  5 Nonnitroglycerin group. *p , 0.01 versus morning control;
†p , 0.01 versus afternoon control; ‡p , 0.01 versus morning Ach24;
§p , 0.01, GTN group versus non-GTN group.
Figure 2. Percent change in mean luminal diameter of the left anterior
descending artery (LAD) coronary artery from baseline, in response to
maximal intracoronary acetylcholine infusion (1024 mol/liter). *p ,
0.01 versus morning control; †p , 0.01 versus afternoon control; ‡p ,
0.05, response in GTN group versus non-GTN group. h 5 Nitroglyc-
erin group. n 5 Nonnitroglycerin group.
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clinical observations concerning the effects of nitrate with-
drawal. In the munitions industry (7,8), and some clinical trials
(9–11), the withdrawal of nitrate therapy was associated with
an increased incidence of acute coronary syndromes. Further-
more, in patients with stable angina it has now been clearly
documented that withdrawal of GTN therapy has adverse
effects on exercise tolerance that persist for up to 12 h during
the nitrate-free period (9,23,24). The present study suggests
that these clinical observations may be secondary to changes in
coronary vasomotor function induced by GTN therapy. The
mechanism by which GTN withdrawal further increased the
vasoconstrictor effects of acetylcholine is not clear. It is prob-
ably related to persisting biochemical changes in the vascula-
ture (induced at the time of the GTN administration) no
longer opposed by the vasodilator effect of the nitrate.
In the GTN group, withdrawal of GTN therapy caused a
significant decrease in coronary diameter between the morning
and afternoon control measurements. The decrease in coro-
nary diameter following removal of transdermal GTN could
have resulted from rebound constriction of the coronary
artery. Alternatively, it may have resulted from the reversal of
continued GTN-induced coronary dilatation. In animal models
(25–27), and in humans (28,29), there is evidence that initial
increases in coronary diameter induced by GTN are lost during
72 h of continuous therapy. This would suggest that the GTN
group had developed tolerance to the effects of transdermal
GTN, and that the decrease in LAD diameter following nitrate
removal represents a rebound effect.
Potential weaknesses. Potential weaknesses of this investi-
gation should be considered. Because endothelium-dependent
responses to acetylcholine are related to risk factors (21), it
would be possible that the different responses of the GTN and
non-GTN group were secondary to imbalances in baseline
characteristics. Although any potential imbalance could have
been avoided using a crossover design, this approach has its
own methodologic problems (30), and would be associated
with important practical and ethical limitations because of the
need for repeat angiography. As randomization resulted in
groups well matched in terms of risk factors, we do not believe
that the different responses found were due to imbalanced
baseline characteristics.
Furthermore, the coronary responses to acetylcholine in the
non-GTN group were similar to the baseline responses of more
than 100 patients with coronary artery disease receiving intra-
coronary acetylcholine in the TREND study (31). This suggests
that the mild constriction observed in the non-GTN group was
typical for this patient population, and that the greater con-
striction observed in the GTN group was the result of the
nitrate. In the present investigation, continuous transdermal
GTN was employed, and it is not known whether the observed
responses to acetylcholine would have been different had an
intermittent regimen been employed. Nevertheless, continuous
nitrate therapy is used in many patients, particularly in the
setting of unstable angina. Furthermore, because there is good
documentation that intermittent regimens are associated with
changes in exercise tolerance and rebound ischemic events
Figure 3. Representative coronary angiograms from
patients in the non-GTN group (left) and in the GTN
group (right). Angiograms were obtained at the time
of the morning control (control), during acetycholine
1024 mol/liter in the morning (AM Ach24), and ace-
tylcholine 1024 mol/liter at the time of the afternoon
study (PM Ach24).
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(9,10,23,24), it seems likely that intermittent therapy may lead
to similar changes in coronary vasomotor function.
Athough short-term administration of low doses of GTN have
shown to enhance coronary vasodilator response to acetylcholine
(32), our findings indicate that long-term administration of clini-
cally relevant doses of GTN is associated with a vasoconstrictive
response to acetylcholine. A number of pharmacologic agents
have been shown to improve endothelial vasomotor function
(17,18,31,33–35). To our knowledge, the present study is the first
report of a commonly used pharmaceutical causing an adverse
effect on endothelium-dependent vasodilatation. We believe
these observations have significant implications concerning the
therapeutic application of long-acting nitrates. The finding that an
organic nitrate increases vasoconstriction in response to an
endothelium-dependent vasodilator serves to emphasize that
there is yet much to be learned concerning a form of therapy that
has been widely used for more than a century.
The authors would like to thank Anne M. Schofield, BSC, RN, for coordinating
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